Colossal Biosciences Hits $10.2B Valuation, Targets Mammoth, Dodo Revival

Sunita Somvanshi

Colossal Biosciences secures $200M funding boost, reaching $10.2B valuation for its ambitious de-extinction projects targeting woolly mammoth, thylacine, and dodo.

Photo Source: Jess Loiterton (Pexels)

With 170+ scientists across labs in Boston, Dallas, and Melbourne, Colossal has assembled 95 top genomics experts to tackle complex biological challenges.

Photo Source: Polina Tankilevitch (Pexels)

Colossal's team generates 99.9% complete ancient genome for thylacine and achieves world's first ancient RNA analysis in separate breakthrough developments.

Photo Source: Polina Tankilevitch (Pexels)

Mammoth project generates first de novo assembled genome, derives pluripotent stem cells from Asian elephants, marking critical progress.

Photo Source: Katie Hollamby (Pexels)

Dodo restoration team develops machine learning approach for identifying genes linked to unique bill morphology, optimizing culture conditions across four bird species

Photo Source: Alexa (Pixabay)

By 2050, over 50% of world's animal species face extinction threat, with current rate at 27,000 species yearly versus natural 10-100 species annually.

Photo Source: Brett Sayles (Pexels)

Colossal Foundation launches as 501(c)(3), partners with 48 conservation groups worldwide to deploy genetic rescue technologies.

Photo Source: Nothing Ahead  (Pexels)

TWG Global leads funding round, recognizing Colossal's innovations at intersection of AI, computational biology, and genetic engineering

Photo Source: Beyza Kaplan (Pexels)

Company develops gene-engineering solution for cane toad toxin resistance to protect endangered Northern Quoll in Australia.

Photo Source: Sérgio Souza (Pexels)

Strategic investors include Robert Nelsen, Peter Jackson, Paul Tudor Jones, and Richard Garriott, supporting Colossal's conservation vision.

Photo Source: Cottonbro Studio(Pexels)